If you or a loved one has been prescribed Reglan (metoclopramide) for gastrointestinal issues, you may have concerns about the risk of tardive dyskinesia, a movement disorder that can become permanent. Understanding the diagnosis and what monitoring steps are recommended is essential for early detection. Building on decades of clinical research into medication-induced movement disorders, this page outlines the key follow-up questions to discuss with your doctor, including FDA-recommended screening intervals and symptom recognition.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis. Its mechanism of action can lead to extrapyramidal side effects, including tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). TD is a hyperkinetic movement disorder caused by dopamine receptor-blocking agents (DRBAs) such as metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition is characterized by involuntary movements of the face, limbs, and trunk, and is associated with increased comorbidities, social stigmatization, and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan regarding the risk of TD. The warning states that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA advises using Reglan for the shortest duration of treatment and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, total treatment duration should be avoided for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warnings and precautions section of the Reglan label further details that metoclopramide can cause TD, a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label advises avoiding concomitant use of other drugs known to cause TD, and avoiding use in patients with Parkinson's Disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Causation considerations for affected patients involve the timeline between exposure and documented harm. While TD typically emerges after prolonged exposure to DRBAs, cases have been reported after a single dose of metoclopramide. A case report describes a nulliparous gynecology patient who developed dyskinetic movements after intraoperative administration of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This patient was found to have several risk factors for TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). Older age is associated with increased risk of TD and with emergence after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/). Once present, TD tends to persist despite dose adjustment or discontinuation of the causative agent (https://pubmed.ncbi.nlm.nih.gov/34703232/).
The adequacy of warnings regarding Reglan and TD is addressed by the FDA's boxed warning, which is the strongest safety warning the agency can issue. The warning clearly states the risk of potentially irreversible TD, the need for shortest duration of use, and the contraindication in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the occurrence of TD after a single dose, as reported in the literature, raises questions about whether prescribers and patients are fully aware of the risk even with short-term use (https://pubmed.ncbi.nlm.nih.gov/34712535/). The label's warning about suppression of TD signs also highlights a potential diagnostic challenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, Reglan (metoclopramide) is causally linked to tardive dyskinesia through its dopamine D2-receptor blocking mechanism. The FDA has issued a boxed warning emphasizing the risk of potentially irreversible TD, with risk increasing with duration and cumulative dose. While TD is more common with prolonged use, cases after a single dose have been documented. Older age is a risk factor for earlier onset and lower dose thresholds. The warnings in the prescribing information are comprehensive, but the potential for TD after short-term use underscores the need for careful risk-benefit assessment and monitoring.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA has issued a boxed warning highlighting this risk, which increases with longer treatment duration and higher cumulative doses. Even a single dose has been reported to trigger TD in some cases (https://pubmed.ncbi.nlm.nih.gov/34712535/).
Risk factors include older age, longer duration of treatment, higher cumulative dosage, and concomitant use of other drugs known to cause TD. Patients with a history of TD should not use Reglan. Older age is associated with earlier onset and lower dose thresholds (https://pubmed.ncbi.nlm.nih.gov/34703232/).
Reglan should be used for the shortest duration necessary, with periodic reassessment. For gastroesophageal reflux, maximum treatment is 12 weeks; for diabetic gastroparesis, avoid longer than 12 weeks. If signs of TD develop, Reglan should be discontinued immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.